<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Med Sci (Basel)</journal-id><journal-id journal-id-type="publisher-id">medsci</journal-id><journal-title-group><journal-title>Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3271</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407550</article-id><article-id pub-id-type="pmc">PMC12101275</article-id>
<article-id pub-id-type="doi">10.3390/medsci13020055</article-id><article-id pub-id-type="publisher-id">medsci-13-00055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Inflammatory Bowel Disease in the Post-STRIDE II Era: Epidemiology and Long-Term Clinical Outcomes from a Population-Based Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ingravalle</surname><given-names>Fabio</given-names></name><xref rid="af1-medsci-13-00055" ref-type="aff">1</xref><xref rid="af2-medsci-13-00055" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Valvano</surname><given-names>Marco</given-names></name><xref rid="af3-medsci-13-00055" ref-type="aff">3</xref><xref rid="af4-medsci-13-00055" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Barbara</surname><given-names>Andrea</given-names></name><xref rid="af5-medsci-13-00055" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Bardhi</surname><given-names>Dorian</given-names></name><xref rid="af6-medsci-13-00055" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6341-5711</contrib-id><name><surname>Latella</surname><given-names>Giovanni</given-names></name><xref rid="af4-medsci-13-00055" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8513-3758</contrib-id><name><surname>Viscido</surname><given-names>Angelo</given-names></name><xref rid="af4-medsci-13-00055" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Campanale</surname><given-names>Mariachiara</given-names></name><xref rid="af3-medsci-13-00055" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4915-7733</contrib-id><name><surname>Vinci</surname><given-names>Antonio</given-names></name><xref rid="af1-medsci-13-00055" ref-type="aff">1</xref><xref rid="af5-medsci-13-00055" ref-type="aff">5</xref><xref rid="af7-medsci-13-00055" ref-type="aff">7</xref><xref rid="c1-medsci-13-00055" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Viora</surname><given-names>Carlo</given-names></name><xref rid="af5-medsci-13-00055" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Bulfone</surname><given-names>Giampiera</given-names></name><xref rid="af8-medsci-13-00055" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1874-5233</contrib-id><name><surname>Mazzotta</surname><given-names>Rocco</given-names></name><xref rid="af9-medsci-13-00055" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5884-161X</contrib-id><name><surname>Maurici</surname><given-names>Massimo</given-names></name><xref rid="af9-medsci-13-00055" ref-type="aff">9</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Torres</surname><given-names>Antoni</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medsci-13-00055"><label>1</label>Doctoral School of Nursing Sciences and Public Health, University of Rome &#x0201c;Tor Vergata&#x0201d;, 00133 Rome, Italy</aff><aff id="af2-medsci-13-00055"><label>2</label>Local Health Authority &#x0201c;Roma 6&#x0201d;, 00041 Albano Laziale, Italy</aff><aff id="af3-medsci-13-00055"><label>3</label>Division of Gastroenterology, Galliera Hospital, 16128 Genoa, Italy</aff><aff id="af4-medsci-13-00055"><label>4</label>Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L&#x02019;Aquila, 67100 L&#x02019;Aquila, Italy</aff><aff id="af5-medsci-13-00055"><label>5</label>Local Health Authority &#x0201c;Roma 1&#x0201d;, 00193 Rome, Italy</aff><aff id="af6-medsci-13-00055"><label>6</label>Health Management Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy</aff><aff id="af7-medsci-13-00055"><label>7</label>Azienda Regionale Emergenza Sanitaria ARES 118, 00149 Rome, Italy</aff><aff id="af8-medsci-13-00055"><label>8</label>Department of Medical, Surgical Science, and Advanced Technology &#x0201c;GF Ingrassia&#x0201d;, University of Catania, 95123 Catania, Italy</aff><aff id="af9-medsci-13-00055"><label>9</label>Department of Biomedicine and Prevention, University of Rome &#x0201c;Tor Vergata&#x0201d;, 00133 Rome, Italy</aff><author-notes><corresp id="c1-medsci-13-00055"><label>*</label>Correspondence: <email>antonio.vinci.at@hotmail.it</email> or <email>antonio.vinci@alumni.uniroma2.eu</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>55</elocation-id><history><date date-type="received"><day>02</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> Inflammatory bowel disease (IBD) includes Crohn&#x02019;s disease (CD) and ulcerative colitis (UC). The availability of an increasing number of new molecules approved for IBD treatment has increased our ability and aspirations to change the trajectory of the disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) II consensus (2018) is the current suggested strategy for IBD management, which recommends a treat-to-target approach. The primary objective of this study is to describe the clinical history of IBD in the post-STRIDE II era and to quantify the burden of IBD in terms of hospitalisation rate. The secondary objective is to estimate the 6-year risk of intestinal resection among IBD patients. <bold>Methods:</bold> A population-based time series analysis was conducted on administrative data; retrospective data from January 2011 to December 2021 were collected for the Local Health Authority &#x0201c;Roma 1&#x0201d; population (&#x0223c;1.5 million residents). Hospitalisation and surgical events were prospectively recorded for patients newly diagnosed between January 2018 and February 2022 (n = 556), with follow-up throughout May 2024. A Kaplan&#x02013;Mayer survivor analysis was performed to estimate the cumulative surgery risk. <bold>Results:</bold> In 2021, the IBD prevalence was 218.3 cases/100,000 people (77.2 CD, 141.1 UC). The incidence trend slowly increased during the last decade, up to 5.3 (CD) and 9.4 (UC) cases/100,000 ppl/year. The yearly hospitalisation rate remained stable, near 16.5%. The 6-year cumulative risk of surgery was 36% for CD and 20% for UC. <bold>Conclusions:</bold> The incidence of IBD has increased in the last few decades, with substantial stability in regard to the incidence of surgery and hospitalisations. Thus, the current IBD management approach has only had a small effect on changing the natural history of the disease.</p></abstract><kwd-group><kwd>inflammatory bowel disease</kwd><kwd>Crohn&#x02019;s disease</kwd><kwd>ulcerative colitis</kwd><kwd>surgery for inflammatory bowel disease</kwd><kwd>inflammatory bowel disease epidemiology</kwd><kwd>population study</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-medsci-13-00055"><title>1. Introduction</title><p>Inflammatory bowel diseases (IBDs), including Crohn&#x02019;s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions with a multifactorial etiopathogenesis affecting the gastrointestinal system and are characterised by periods of relapse and remission and a progressive nature, leading to bowel damage and disability [<xref rid="B1-medsci-13-00055" ref-type="bibr">1</xref>,<xref rid="B2-medsci-13-00055" ref-type="bibr">2</xref>]. Clinical, endoscopic, and radiologic assessments are often used to predict long- and mid-term patient outcomes [<xref rid="B3-medsci-13-00055" ref-type="bibr">3</xref>,<xref rid="B4-medsci-13-00055" ref-type="bibr">4</xref>].</p><p>The burden of IBD is increasing worldwide and, in the past decade, IBD has emerged as a public health challenge [<xref rid="B5-medsci-13-00055" ref-type="bibr">5</xref>,<xref rid="B6-medsci-13-00055" ref-type="bibr">6</xref>]. The estimated prevalence (&#x0003e;0.3%) of IBD continues to rise in Western countries, with a high burden of disease in North America, Oceania, and Europe, while newly industrialised countries in Asia, Africa, and South America are showing a progression in terms of IBD prevalence, as they become more westernised and urbanised [<xref rid="B7-medsci-13-00055" ref-type="bibr">7</xref>].</p><p>Four epidemiological stages of IBD have been proposed to explain the evolution of IBD across the epidemiologic transition periods. The four stages are as follows: (1) emergence, (2) acceleration of incidence, (3) compounding prevalence, and (4) prevalence equilibrium. Western countries (i.e., most countries in North America, Western Europe, and Oceania) are in stage 3 (compounding prevalence), where IBD prevalence exceeds 0.5%. Newly industrialised countries in Asia, Latin America, and the Middle East are in stage 2 (acceleration of incidence), with a low prevalence but rapidly increasing incidence [<xref rid="B8-medsci-13-00055" ref-type="bibr">8</xref>].</p><p>In the last decade, a paradigm shift in IBD management has occurred [<xref rid="B9-medsci-13-00055" ref-type="bibr">9</xref>]. Both quality of life (QoL) and clinical endpoints are now a target of interventions. Prevention measures (such as smoking prevention, reducing stress factors, and a particular focus on younger age groups) have been proposed in recent times that have a debatable role on the causal effects of the disease, but that have had a notable impact on symptom reduction [<xref rid="B10-medsci-13-00055" ref-type="bibr">10</xref>,<xref rid="B11-medsci-13-00055" ref-type="bibr">11</xref>,<xref rid="B12-medsci-13-00055" ref-type="bibr">12</xref>]. Alternative measures for QoL improvements have also been proposed, such as telemedicine, the use of which is already suggested for patient monitoring and supervision by several clinical studies, and is even recommended in a recent position paper by the European Federation of Internal Medicine [<xref rid="B13-medsci-13-00055" ref-type="bibr">13</xref>,<xref rid="B14-medsci-13-00055" ref-type="bibr">14</xref>]. On the pharmacological front, the availability of an increasing number of new molecules (including adjuvants, biological therapies, and small molecules) has increased our ability and aspirations to reach beyond the conventional treatment goals, such as clinical remission [<xref rid="B15-medsci-13-00055" ref-type="bibr">15</xref>,<xref rid="B16-medsci-13-00055" ref-type="bibr">16</xref>,<xref rid="B17-medsci-13-00055" ref-type="bibr">17</xref>]. Despite the current therapies available, a proportion of patients experience relapses and continuous inflammation, which occasionally requires the surgical removal of parts of their intestine [<xref rid="B18-medsci-13-00055" ref-type="bibr">18</xref>]. The treat-to-target approach, designed to obtain an even more ambitious objective, represents the current strategy in IBD management [<xref rid="B19-medsci-13-00055" ref-type="bibr">19</xref>,<xref rid="B20-medsci-13-00055" ref-type="bibr">20</xref>]. STRIDE I, proposed in 2015, was the first consensus oriented towards this paradigmatic shift [<xref rid="B21-medsci-13-00055" ref-type="bibr">21</xref>]. The valuable lessons gained from this consensus were subsequently developed into the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) II consensus in 2018 [<xref rid="B22-medsci-13-00055" ref-type="bibr">22</xref>]. However, despite the novel treatments available and the new tight control strategies, including targeted and customised therapies, and the attention being paid towards the patients&#x02019; immunocompetence or immunosuppression via dedicated vaccination schedules, the burden of disease, and, in particular, the need to reduce the risk of surgery and hospitalisation, represents a significant unmet need [<xref rid="B23-medsci-13-00055" ref-type="bibr">23</xref>,<xref rid="B24-medsci-13-00055" ref-type="bibr">24</xref>].</p><sec id="sec1dot1-medsci-13-00055"><title>1.1. IBD Within the Healthcare System in Italy</title><p>In regard to the Italian National Healthcare System (NHS), individuals are required to pay a contribution fee for certain health services. They do not pay the entire cost of the service; instead, they contribute a portion of the cost, and the rest is covered by the NHS. Depending on the clinical and/or socio-economic conditions, specific individuals have an exemption right in regard to the requirement to pay a contribution fee. To obtain an exemption, specific criteria must be met. In particular, for IBD patients, after an endoscopic and histological evaluation, a gastroenterology specialist can certify the illness condition by issuing a healthcare certificate that exempts the IBD patient from being required to pay the contribution fee. After a diagnosis, healthcare approval by the NHS is quite fast, usually only requiring up to two weeks [<xref rid="B25-medsci-13-00055" ref-type="bibr">25</xref>]. After approval, all IBD-related health services are registered by the NHS as provided to the specific patient. A table of procedures that the NHS classifies as IBD-related is available in <xref rid="medsci-13-00055-t0A1" ref-type="table">Table A1</xref>.</p><p>Concerning hospital services, Italian NHS is a Beveridge Health System which has adopted DRG payments to hospitals; Italian DRGs follow the US (CMS) model ver. 24.0. In order to obtain a DRG payment, each structure must generate and transmit a Hospital Discharge Forms (SDO&#x02014;Scheda Dimissione Ospedaliera), in anonymous form, for every admitted patient [<xref rid="B26-medsci-13-00055" ref-type="bibr">26</xref>]. SDOs are transmitted monthly to Regional Governments, who proceed to refund the hospital structures, and are also transmitted periodically to the Ministry of Health for statistical and administrative purposes.</p></sec><sec id="sec1dot2-medsci-13-00055"><title>1.2. Study Objectives</title><p>The primary objective of this study is to define the incidence and prevalence of IBD from 2011 to 2021. The secondary objective is to quantify the risk of surgery among IBD patients up until 2024 in order to understand whether the diffusion and application of the STRIDE II guidelines resulted in a change in IBD-related hospitalisation rates and surgery events.</p></sec></sec><sec id="sec2-medsci-13-00055"><title>2. Materials and Methods</title><sec id="sec2dot1-medsci-13-00055"><title>2.1. Study Design and Reporting</title><p>This study was designed in two components. First, there is an epidemiological description of IBD in the interested territory, conducted as a population-based interrupted time series, with data collected from routinely used administrative records referring to the years 2011&#x02013;2021. Second, the data of all patients with diagnosed IBD from January 2018 to February 2022 were collected and analysed prospectively. The REporting of studies Conducted using Observational Routinely-collected Data (RECORD) guidelines were used for reporting [<xref rid="B27-medsci-13-00055" ref-type="bibr">27</xref>].</p></sec><sec id="sec2dot2-medsci-13-00055"><title>2.2. Population and Data Sources</title><p>The population comprises all living residents in the administrative jurisdiction of &#x0201c;Roma 1&#x0201d; Local Health Authority (LHA) in Rome, Italy, which encompasses the Northwestern sector of the urban territory of Rome, Italy. It hosts more than 15 hospital structures within its territory, including 2 directly managed hospital facilities, 3 publicly run Hospitals, and 13 Emergency Departments (out of 22 in the Rome metropolitan area) [<xref rid="B28-medsci-13-00055" ref-type="bibr">28</xref>].</p><p>Complete data regarding new IBD diagnoses were available from January 2011 to December 2021. These data were used for incidence and prevalence estimation. Data regarding older diagnoses was available, but with no extra information regarding the diagnosis date; this was utilised only for prevalence estimation. Data regarding hospitalisation from either public or private facilities, both inside or outside the LHA Roma 1 territory, was available from January 2018 to May 2024 and was used to describe hospitalisation trends.</p><p>Data were collected in pseudo-anonymized form via the digital Business Intelligence (BI) platform routinely used in LHA Roma 1: the ID code of each person is represented by an encrypted string, yet it is still possible to connect health events attributable to the same individual. Using this pseudo-anonymized ID, information from several sources (Exemptions registry, SDO database).</p><p>This study included person-level linkage between the exemptions registry and SDO repository. Linkage was executed automatically using Roma 1 BI software. A detailed list of the administrative datasets used in this study is provided in <xref rid="medsci-13-00055-t0A2" ref-type="table">Table A2</xref>.</p><p>Data availability and cohort composition are depicted in <xref rid="medsci-13-00055-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec2dot3-medsci-13-00055"><title>2.3. Outcome Definitions</title><p>The date each patient obtained IBD ticket exemption was used as proxy for IBD diagnosis (there may be a few days in delay between clinical diagnosis and administrative exemption recording). Patients have a strong incentive to obtain their exemption recorded since they incur no charges for visits and drugs related to their pathology. For this reason, there is very low chance of missing diagnosis data.</p><p>For the retrospective section of the study, as per current practice in population studies, we defined an IBD-related hospitalisation based on the presence of an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis of either CD or UC as the most responsible comorbidity, or primary inter-service or inter-hospital transfer diagnosis [<xref rid="B29-medsci-13-00055" ref-type="bibr">29</xref>,<xref rid="B30-medsci-13-00055" ref-type="bibr">30</xref>].</p><p>For the prospective section of the study, surgical treatments unrelated to IBD, including infectious, biliopancreatic, and traumatic, have not been considered as IBD-related and were therefore excluded from the analysis. A comprehensive list of codes and procedures included and excluded is available in <xref rid="medsci-13-00055-t0A3" ref-type="table">Table A3</xref>.</p></sec><sec id="sec2dot4-medsci-13-00055"><title>2.4. Statistical Methods</title><sec id="sec2dot4dot1-medsci-13-00055"><title>2.4.1. Retrospective Analysis</title><p>The monthly incidence of IBD (distinguished as either UC or CD) among the general population in LHA Roma 1 was calculated for each age range (stratified in 10-year age groups) and for each observation year from January 2011 to December 2021; standardisation was performed based on the 2024 LHA Roma 1 population composition. Age-standardised incidence was calculated annually, and separate linear regression models were used to test for any statistically significant increases observed during the 10-year timespan. As a sensitivity analysis, monthly data were filtered using the Baxter&#x02013;King method for time series decomposition [<xref rid="B31-medsci-13-00055" ref-type="bibr">31</xref>]. The trend component was isolated and compared with actual observations (after the flat mean of residuals was added back, to correct for underestimation due to filtering out both stochastic and cyclic components) following simple smoothing using a 3-period simple autoregressive moving average (3-ARMA).</p><p>The monthly hospitalisation trend among the cohort of IBD patients residing in Roma 1 (N = 2191) was calculated from January 2018 to May 2024 using time series decomposition, as per primary analysis. The hospitalisation trend was also described as a yearly percentage among IBD patients.</p><p>Statistical analysis was conducted at the Department of Biomedicine and Prevention, University of Rome &#x0201c;Tor Vergata&#x0201d;. MS Excel v.2016 and Stata v.17 were used for calculations and graph creation.</p></sec><sec id="sec2dot4dot2-medsci-13-00055"><title>2.4.2. Prospective Analysis</title><p>A cohort of 556 patients diagnosed from January 2018 to February 2022 was included in the prospective analysis. All hospitalisations were screened until May 2024, and recorded interventions were considered as per primary outcome if a relevant ICD-9-CM procedure was registered. A table of relevant procedures is available in <xref rid="medsci-13-00055-t0A3" ref-type="table">Table A3</xref>.</p><p>The Kaplan&#x02013;Meier function was then proposed to estimate the cumulative risk for surgery among IBD patients, both in raw data and after adjustment for gender and age at diagnosis via a Cox proportional hazards model.</p></sec><sec id="sec2dot4dot3-medsci-13-00055"><title>2.4.3. Bias and Bias Reduction</title><p>A possible source of bias lies in the underestimation of actual IBD cases due to misdiagnosis or difficult diagnosis, especially for people coming from rural areas, where IBD may require differential diagnosis with other gastrointestinal conditions. The risk of our results being significantly affected is, however, very low in magnitude because most of the included population comes from a heavily urbanised area and because difficult-to-diagnose IBD should contribute minimally to overall hospitalisations and treatment effects.</p><p>Another possible source of bias is linked to the retrospective nature of this study, as we could not select patients by excluding confounding factors. No information was available regarding clinical presentation or specific risk factors such as drinking or smoking habits; however, adjustment for gender and age at diagnosis was possible, and, as such, we performed it in the inferential analysis.</p></sec></sec></sec><sec sec-type="results" id="sec3-medsci-13-00055"><title>3. Results</title><sec id="sec3dot1-medsci-13-00055"><title>3.1. IBD Epidemiology</title><p>Details on yearly IBD incidence are provided in <xref rid="medsci-13-00055-t001" ref-type="table">Table 1</xref>. A total of 2859 patients were diagnosed with IBD from January 2011 to December 2021. The raw incidence of IBD increased slowly in the observed period: new diagnoses of IBD rose from 184 in 2011 to 341 in 2021, increasing from 14.7 to 28.5 &#x000d7; 100,000 ab per year (average: 21.2). <xref rid="medsci-13-00055-f002" ref-type="fig">Figure 2</xref> depicts monthly observations and trend components, filtered for cyclical effects via the Baxter&#x02013;King method. <xref rid="medsci-13-00055-f003" ref-type="fig">Figure 3</xref> illustrates the population composition by age and gender, both currently and at the time of the diagnosis. For the 2191 patients diagnosed since 2011 and currently residing in Roma 1, the hospitalisation trend in the last 6 years was calculated (<xref rid="medsci-13-00055-f004" ref-type="fig">Figure 4</xref>). The raw hospitalisation rate remained relatively constant throughout the study period, with 1.38 hospitalisations/100,000 ppl per month. This roughly translates to 16.5% yearly hospitalisation rate among IBD patients. The prevalence of IBD is estimated to be 218.3 cases/100,000 ppl, with 77.2 cases of CD and 141.1 cases of UC.</p></sec><sec id="sec3dot2-medsci-13-00055"><title>3.2. Prospective Cohort</title><p>Of the 556 patients constituting the prospective cohort, 194 (34.9%) had CD and 362 (65.1%) UC. Demographic details are available in <xref rid="medsci-13-00055-t002" ref-type="table">Table 2</xref>. The mean follow-up time was approximately 6 years (SD: 10 months).</p><p>Among the 196 CD patients (110 M, 86 F), 19 (9.8%) surgery events occurred. In total, 2 of them coincided with the diagnosis moment; thus, acute presentation can be estimated to happen in 1.0% of all cases. The Kaplan&#x02013;Meier function shows a 27% cumulative risk of surgery at 6 years from diagnosis, after adjusting for gender and age at diagnosis, while unadjusted estimates indicate a 12% cumulative risk of surgery after 6 years.</p><p>Among the 362 UC patients (190 M, 172 F), 15 (4.1%) surgery interventions occurred, with acute presentation observed in 12 cases (3.3% of patients). Adjusted Kaplan&#x02013;Meier function shows a 2% cumulative risk of having surgery at 6 years, while observed surgery cumulative risk was close to 5% (<xref rid="medsci-13-00055-f005" ref-type="fig">Figure 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-medsci-13-00055"><title>4. Discussion</title><sec id="sec4dot1-medsci-13-00055"><title>4.1. Key Results</title><p>A small increase in IBD incidence in the last decade was observed in our population study, with an average yearly estimated incidence of 21.2 cases &#x000d7;100,000 ppl. This increasing trend has also been noted elsewhere, for both CD and UC [<xref rid="B6-medsci-13-00055" ref-type="bibr">6</xref>,<xref rid="B32-medsci-13-00055" ref-type="bibr">32</xref>,<xref rid="B33-medsci-13-00055" ref-type="bibr">33</xref>]. The reasons for this increase are largely unknown. Both improved diagnostic accuracy and greater patient awareness may have contributed to the rise in new IBD diagnoses. Nevertheless, unknown environmental factors might also play a key role in increasing IBD prevalence [<xref rid="B34-medsci-13-00055" ref-type="bibr">34</xref>].</p><p>Robust data from a review of population-based studies (in the pre-STRIDE era) demonstrate that between 27% and 50% of CD patients require surgery between 5 and 10 years after diagnosis, respectively, with a hospitalisation rate of 20% per year. However, in these studies, no data from the biological era were available [<xref rid="B35-medsci-13-00055" ref-type="bibr">35</xref>,<xref rid="B36-medsci-13-00055" ref-type="bibr">36</xref>]. In our study, the Kaplan&#x02013;Meier analysis showed that the cumulative 6-year risk of surgery was 27% and 2% from diagnosis in CD and UC, respectively (adjusted for gender and age at diagnosis), while the hospitalisation rate was 16.5% for IBD patients.</p></sec><sec id="sec4dot2-medsci-13-00055"><title>4.2. Strengths and Limitations</title><p>A significant strength of this study is the use of data with little to no missing records. This was possible because informatics systems do not allow for the treating physician to proceed with a medical record when information on exemption, diagnosis, or clinical procedure is missing; also, the physician is warned when apparent incongruences are detected by the system (such as a surgical procedure registered within a psychiatric ward DRG), allowing them to correct occasional mistakes. Moreover, use of population databanks allowed us to have a minimal risk of excluding actual IBD patients from our analysis. This is also true for procedures where the patients were exempt from paying a contribution fee, as the prescription charge exemption is recorded and linked to the specific procedure.</p><p>Another strength of this study is that, during the considered period, no substantial modifications in IBD management strategy occurred. No new molecules were approved, and the STRIDE II approach was proposed at the beginning of the enrolment period. This aspect makes the reported results extremely representative of the current situation. However, baseline characteristics concerning relevant factors that can contribute to the risk of surgery, such as smoking habits and disease patterns, were not available in our database.</p></sec><sec id="sec4dot3-medsci-13-00055"><title>4.3. Interpretation and Generalisability</title><p>The availability of an increasing number of new molecules approved for IBD treatment has heightened our aspirations to alter the disease&#x02019;s natural history. Changes in the paradigm of IBD management with treat-to-target strategies and the spread of the STRIDE approach are significant sources of bias that make it difficult to evaluate the role of biological therapies in the decline of IBD-related surgery and hospitalisation. Likewise, the widespread use of new therapies affects the changing incidence of these outcomes.</p><p>In recent times, few population-based studies have attempted to address the evolution of IBD-related surgery and hospitalisation over the years. A UK population-based cohort study evaluated the 5-year risk of surgery in four cohorts followed from 2000 to 2017. The 5-year cumulative risk of surgery was 20.4% in cohort 1 (2000&#x02013;2004), 18.3% in cohort 2 (2005&#x02013;2008), 14.7% in cohort 3 (2009&#x02013;2013), and 13.0% in cohort 4 (2014&#x02013;2017). Conversely, the prevalence of biological therapies prescriptions increased in each of the cohorts considered. Thus, the authors concluded that increased and earlier use of biologic therapy in CD patients corresponded with a decreasing requirement for surgery over time [<xref rid="B37-medsci-13-00055" ref-type="bibr">37</xref>]. On the other hand, a Canadian population-based interrupted time series study evaluated the effect of the marketplace introduction of infliximab on population rates of hospitalisations and surgeries. Infliximab did not produce significant declines in the rates of CD-related hospitalisations (OR 1.06, 95% CI from 0.811 to 1.39) or surgeries (OR 1.10, 95% CI from 0.810 to 1.50), or in the rates of UC-related hospitalisations (OR 1.22, 95% CI from 1.07 to 1.39) or colectomies (OR 0.933, 95% CI from 0.54 to 1.61) [<xref rid="B29-medsci-13-00055" ref-type="bibr">29</xref>]. In Italy, another retrospective study conducted over a different population showed that the introduction of biological therapies had only a slight impact on the occurrence of surgery in CD patients over a long observation period, contributing to delaying the first intestinal resection [<xref rid="B38-medsci-13-00055" ref-type="bibr">38</xref>]. Furthermore, despite the increased post-operative use of anti-TNF&#x003b1; agents in CD patients in the last two decades, the impact of this strategy on the risk of the long-term re-operation rate has been modest [<xref rid="B39-medsci-13-00055" ref-type="bibr">39</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-medsci-13-00055"><title>5. Conclusions</title><p>A slight increase in the raw incidence of IBD has been observed in recent decades, with substantial stability in the incidence of surgeries and hospitalisations. However, the estimated incidence and prevalence of IBD are still slightly lower than in other Western countries. This could be due to underdiagnoses or an actual lower incidence among the Italian population. Hospitalisation and surgery rates have also remained stable over the past decade. Therefore, changes in current IBD management appear to have had only a small effect on altering the natural history of the disease.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.B., M.C., M.V. and A.V. (Antonio Vinci); methodology, F.I., M.M., M.V., C.V. and A.V. (Antonio Vinci); software, A.B.; validation, G.B., M.M., M.V., R.M. and G.L.; formal analysis, F.I., M.M, M.V. and A.V. (Antonio Vinci); investigation, A.B., C.V. and A.V. (Antonio Vinci); resources, A.V. (Antonio Vinci), M.M. and R.M.; data curation, A.V. (Antonio Vinci); writing&#x02014;original draft preparation, F.I., M.M., M.V. and A.V. (Antonio Vinci); writing&#x02014;review and editing, A.B., D.B., G.B., M.C., A.V. (Antonio Vinci), A.V. (Angelo Viscido) and G.L.; visualisation, A.V. (Antonio Vinci); supervision, G.L. and G.B.; project administration, A.V. (Antonio Vinci) and A.V. (Angelo Viscido); funding acquisition, M.M. and R.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This is a register-based research project with no contact with patients, their relatives, or treating physicians. Ethical Review board Lazio 1 approved the study (prot. n&#x000b0; 0593/2024). All authors had access to the study data and have reviewed and approved the final manuscript.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are the property of ASL Roma 1 Public Health Authority. Data are available from the Roma 1 Institutional Data Access (e-mail at: <email>protocollo@pec.aslroma1.it</email>) for researchers who meet the criteria for access to confidential data.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ARMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Auto-Regressive Moving Average</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD</td><td align="left" valign="middle" rowspan="1" colspan="1">Crohn&#x02019;s Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DRG</td><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis-Related Group</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IBD</td><td align="left" valign="middle" rowspan="1" colspan="1">Inflammatory Bowel Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICD-9-CM</td><td align="left" valign="middle" rowspan="1" colspan="1">International Classification of Diseases, 9th Revision, Clinical Modification</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LHA</td><td align="left" valign="middle" rowspan="1" colspan="1">Local Health Authority</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NHS</td><td align="left" valign="middle" rowspan="1" colspan="1">National Healthcare System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PPL</td><td align="left" valign="middle" rowspan="1" colspan="1">People</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QOL</td><td align="left" valign="middle" rowspan="1" colspan="1">Quality of Life</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SDO</td><td align="left" valign="middle" rowspan="1" colspan="1">Scheda di Dimissione Ospedaliera (hospital discharge form)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UC</td><td align="left" valign="middle" rowspan="1" colspan="1">Ulcerative Colitis</td></tr></tbody></array></p></glossary><app-group><app id="app1-medsci-13-00055"><title>Appendix A</title><table-wrap position="anchor" id="medsci-13-00055-t0A1"><object-id pub-id-type="pii">medsci-13-00055-t0A1_Table A1</object-id><label>Table A1</label><caption><p>List of possible services provided by the NHS for free to patients with IBD diagnosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Health Service with Ticket Exemption</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Note</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>CHECK-UP VISIT NECESSARY TO MONITOR THE DISEASE, THE MOST FREQUENT COMPLICATIONS AND TO PREVENT FURTHER WORSENING</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="18" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>VENOUS BLOOD SAMPLING</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ALANINE AMINOTRANSFERASE (ALT) (GPT)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALPHA 1 ACID GLYCOPROTEIN</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASPARTATE AMINOTRANSFERASE (AST) (GOT)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">REFLEX BILIRUBIN (cut-off &#x0003e; 1 mg/dL unless more restrictive cut-offs are defined at a regional level. Included: Direct and Indirect Bilirubin</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COBALAMIN (VIT. B12)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FERRITIN</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IRON</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FOLATE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALKALINE PHOSPHATASE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GAMMA-GLUTAMILTRANSFERASE (gamma GT)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PANCREATIC LIPASE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POTASSIUM</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BLOOD PROTEINS (ELECTROPHORESIS) Included: Total protein determination 90.38.5</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SODIUM</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRANSFERRIN</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BLOOD CHROME: BLOOD CYTOMETRY EXAM AND DIFFERENTIAL LEUKOCYTE COUNT Hb, GR, GB, HCT, PLT, IND. DERIV. Including any microscopic control</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C-REACTIVE PROTEIN (Quantitative)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BLOOD SEDIMENTATION RATE (ESR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RADIOLOGY</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TRADITIONAL</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">DOUBLE CONTRAST COLON ENEMA</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOUBLE CONTRAST SMALL BOW ENEMA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>ULTRASOUND</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ULTRASOUND OF THE COMPLETE ABDOMEN</td><td align="left" valign="middle" rowspan="1" colspan="1">Possible Colour-Doppler integration</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ULTRASOUND OF THE INTESTINAL LOOP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>DENSITOMETRY</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">BONE DENSITOMETRY. LUMBAR DXA</td><td align="left" valign="middle" rowspan="1" colspan="1">No more than 1 in 12&#x02013;18 months</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BONE DENSITOMETRY. FEMORAL DXA</td><td align="left" valign="middle" rowspan="1" colspan="1">No more than 1 in 12&#x02013;18 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BONE DENSITOMETRY. ULTRADISTAL DXA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No more than 1 in 12&#x02013;18 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>ENDOSCOPY</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>UPPER SITES</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ESOPHAGOGASTRODUODENOSCOPY [EGDS]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BIOPSY DURING EGDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Brushing or washing for sample collection</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIOPSY OF THE SMALL INTESTINE DURING ENTEROSCOPY</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brushing or washing for sample collection</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>LOWER SITES</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TOTAL COLONOSCOPY WITH FLEXIBLE ENDOSCOPE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RECTOSIGMOIDOSCOPY WITH FLEXIBLE ENDOSCOPE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PROCTORECTORECTOSIGMOIDOSCOPY WITH RIGID ENDOSCOPE</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SINGLE SITE BIOPSY OF THE LARGE INTESTINE DURING TOTAL COLONOSCOPY WITH FLEXIBLE TUBE</td><td align="left" valign="middle" rowspan="1" colspan="1">Brushing or washing for sample collection</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIOPSY DURING PROCTORECTOSIGMOIDOSCOPY</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brushing or washing for sample collection</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="medsci-13-00055-t0A2"><object-id pub-id-type="pii">medsci-13-00055-t0A2_Table A2</object-id><label>Table A2</label><caption><p>Roma 1 administrative databases used to capture study information.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Database</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>IBD PATIENT STATUS</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Roma 1 ticket exemptions database</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>IBD PATIENTS DIAGNOSIS DATE</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Roma 1 ticket exemptions database</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>DEMOGRAPHIC VARIABLES</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Roma 1 healthcare-registered persons database</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>SURGERY INTERVENTIONS</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Roma 1 hospital records administrative database</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>HOSPITALISATIONS</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roma 1 hospital records administrative database</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="medsci-13-00055-t0A3"><object-id pub-id-type="pii">medsci-13-00055-t0A3_Table A3</object-id><label>Table A3</label><caption><p>Table of ICD-9CM codes used as surgical intervention outcome in prospective cohort analysis. *: excluded for Ulcerative Colitis cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ICD Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Meaning</th></tr></thead><tbody><tr><td colspan="2" align="center" valign="middle" rowspan="1">ibd-Related (included):</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 42.33</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic Excision Or Destruction Of Lesion Or Tissue Of Esophagus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 42.52</td><td align="center" valign="middle" rowspan="1" colspan="1">Intrathoracic Esophagogastrostomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 43.91</td><td align="center" valign="middle" rowspan="1" colspan="1">Total Gastrectomy With Intestinal Interposition</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 45.30</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic Excision Or Destruction Of Lesion Of Duodenum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 45.62</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Partial Resection Of Small Intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 45.72</td><td align="center" valign="middle" rowspan="1" colspan="1">Open And Other Cecectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.73</td><td align="center" valign="middle" rowspan="1" colspan="1">Open And Other Right Hemicolectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.75</td><td align="center" valign="middle" rowspan="1" colspan="1">Open And Other Left Hemicolectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.79</td><td align="center" valign="middle" rowspan="1" colspan="1">Other And Unspecified Partial Excision Of Large Intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Total Intra-Abdominal Colectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.91</td><td align="center" valign="middle" rowspan="1" colspan="1">Small-To-Small Intestinal Anastomosis</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.93</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Small-To-Large Intestinal Anastomosis</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.94</td><td align="center" valign="middle" rowspan="1" colspan="1">Large-To-Large Intestinal Anastomosis</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.02</td><td align="center" valign="middle" rowspan="1" colspan="1">Resection Of Exteriorized Segment Of Small Intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.81</td><td align="center" valign="middle" rowspan="1" colspan="1">Intra-Abdominal Manipulation Of Small Intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.63</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Anterior Resection Of Rectum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.69</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Resection Of Rectum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.93</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Incision Of Anus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.21</td><td align="center" valign="middle" rowspan="1" colspan="1">Laparoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 54.3</td><td align="center" valign="middle" rowspan="1" colspan="1">Excision Or Destruction Of Lesion Or Tissue Of Abdominal Wall Or Umbilicus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 54.63</td><td align="center" valign="middle" rowspan="1" colspan="1">Other Suture Of Abdominal Wall</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* 83.39</td><td align="center" valign="middle" rowspan="1" colspan="1">Excision Of Lesion Of Other Soft Tissue</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">Not IBD-Related (Excluded):</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.16</td><td align="center" valign="middle" rowspan="1" colspan="1">Esophagogastroduodenoscopy [EGD] with closed biopsy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.19</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on small intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.23</td><td align="center" valign="middle" rowspan="1" colspan="1">Colonoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.24</td><td align="center" valign="middle" rowspan="1" colspan="1">Flexible sigmoidoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.25</td><td align="center" valign="middle" rowspan="1" colspan="1">Closed [endoscopic] biopsy of large intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.26</td><td align="center" valign="middle" rowspan="1" colspan="1">Open biopsy of large intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.27</td><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal biopsy, site unspecified</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.28</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on large intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.29</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on intestine, site unspecified</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.23</td><td align="center" valign="middle" rowspan="1" colspan="1">Rigid proctosigmoidoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.24</td><td align="center" valign="middle" rowspan="1" colspan="1">Closed [endoscopic] biopsy of rectum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.25</td><td align="center" valign="middle" rowspan="1" colspan="1">Open biopsy of rectum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.29</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on rectum, rectosigmoid and perirectal tissue</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.36</td><td align="center" valign="middle" rowspan="1" colspan="1">[Endoscopic] polypectomy of rectum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.21</td><td align="center" valign="middle" rowspan="1" colspan="1">Anoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.29</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on anus and perianal tissue</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50.11</td><td align="center" valign="middle" rowspan="1" colspan="1">Closed (percutaneous) [needle] biopsy of liver</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic retrograde cholangiopancreatography [ERCP]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.11</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic retrograde cholangiography [ERC]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.24</td><td align="center" valign="middle" rowspan="1" colspan="1">Closed [percutaneous] [needle] biopsy of intra-abdominal mass</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Colostomy, not otherwise specified</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.11</td><td align="center" valign="middle" rowspan="1" colspan="1">Temporary colostomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.2</td><td align="center" valign="middle" rowspan="1" colspan="1">Ileostomy, not otherwise specified</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.21</td><td align="center" valign="middle" rowspan="1" colspan="1">Temporary ileostomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.23</td><td align="center" valign="middle" rowspan="1" colspan="1">Other permanent ileostomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.51</td><td align="center" valign="middle" rowspan="1" colspan="1">Closure of stoma of small intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.73</td><td align="center" valign="middle" rowspan="1" colspan="1">Closure of other rectal fistula</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.51</td><td align="center" valign="middle" rowspan="1" colspan="1">Left lateral anal sphincterotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.59</td><td align="center" valign="middle" rowspan="1" colspan="1">Other anal sphincterotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">Imageless computer assisted surgery</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Excision or destruction of lesion or tissue of tongue</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25.2</td><td align="center" valign="middle" rowspan="1" colspan="1">Partial glossectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27.29</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on oral cavity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27.42</td><td align="center" valign="middle" rowspan="1" colspan="1">Wide excision of lesion of lip</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27.49</td><td align="center" valign="middle" rowspan="1" colspan="1">Other excision of mouth</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27.56</td><td align="center" valign="middle" rowspan="1" colspan="1">Other skin graft to lip and mouth</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27.79</td><td align="center" valign="middle" rowspan="1" colspan="1">Other operations on uvula</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30.09</td><td align="center" valign="middle" rowspan="1" colspan="1">Other excision or destruction of lesion or tissue of larynx</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30.22</td><td align="center" valign="middle" rowspan="1" colspan="1">Vocal cordectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40.41</td><td align="center" valign="middle" rowspan="1" colspan="1">Radical neck dissection, unilateral</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">41.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Total splenectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">42.33</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic excision or destruction of lesion or tissue of esophagus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">42.52</td><td align="center" valign="middle" rowspan="1" colspan="1">Intrathoracic esophagogastrostomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">43.89</td><td align="center" valign="middle" rowspan="1" colspan="1">Other partial gastrectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">43.91</td><td align="center" valign="middle" rowspan="1" colspan="1">Total gastrectomy with intestinal interposition</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44.19</td><td align="center" valign="middle" rowspan="1" colspan="1">Other diagnostic procedures on stomach</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44.43</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic control of gastric or duodenal bleeding</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44.67</td><td align="center" valign="middle" rowspan="1" colspan="1">Laparoscopic procedures for creation of esophagogastric sphincteric competence</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">44.68</td><td align="center" valign="middle" rowspan="1" colspan="1">Laparoscopic gastroplasty</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.13</td><td align="center" valign="middle" rowspan="1" colspan="1">Other endoscopy of small intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45.42</td><td align="center" valign="middle" rowspan="1" colspan="1">Endoscopic polypectomy of large intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.81</td><td align="center" valign="middle" rowspan="1" colspan="1">Intra-abdominal manipulation of small intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">46.85</td><td align="center" valign="middle" rowspan="1" colspan="1">Dilation of intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.76</td><td align="center" valign="middle" rowspan="1" colspan="1">Other proctopexy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">48.93</td><td align="center" valign="middle" rowspan="1" colspan="1">Repair of perirectal fistula</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.11</td><td align="center" valign="middle" rowspan="1" colspan="1">Anal fistulotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.12</td><td align="center" valign="middle" rowspan="1" colspan="1">Anal fistulectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.73</td><td align="center" valign="middle" rowspan="1" colspan="1">Closure of anal fistula</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">49.93</td><td align="center" valign="middle" rowspan="1" colspan="1">Other incision of anus</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50.22</td><td align="center" valign="middle" rowspan="1" colspan="1">Partial hepatectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50.3</td><td align="center" valign="middle" rowspan="1" colspan="1">Lobectomy of liver</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.04</td><td align="center" valign="middle" rowspan="1" colspan="1">Other cholecystotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.22</td><td align="center" valign="middle" rowspan="1" colspan="1">Cholecystectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.23</td><td align="center" valign="middle" rowspan="1" colspan="1">Laparoscopic cholecystectomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.83</td><td align="center" valign="middle" rowspan="1" colspan="1">Pancreatic sphincteroplasty</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">51.98</td><td align="center" valign="middle" rowspan="1" colspan="1">Other percutaneous procedures on biliary tract</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.11</td><td align="center" valign="middle" rowspan="1" colspan="1">Exploratory laparotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.19</td><td align="center" valign="middle" rowspan="1" colspan="1">Other laparotomy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.21</td><td align="center" valign="middle" rowspan="1" colspan="1">Laparoscopy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.91</td><td align="center" valign="middle" rowspan="1" colspan="1">Percutaneous abdominal drainage</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">54.95</td><td align="center" valign="middle" rowspan="1" colspan="1">Incision of peritoneum</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">70.52</td><td align="center" valign="middle" rowspan="1" colspan="1">Repair of rectocele</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">70.73</td><td align="center" valign="middle" rowspan="1" colspan="1">Repair of rectovaginal fistula</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.63</td><td align="center" valign="middle" rowspan="1" colspan="1">Full-thickness skin graft to other sites</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.69</td><td align="center" valign="middle" rowspan="1" colspan="1">Other free skin graft</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.7</td><td align="center" valign="middle" rowspan="1" colspan="1">Pedicle or flap graft, not otherwise specified</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.72</td><td align="center" valign="middle" rowspan="1" colspan="1">Advancement of pedicle graft</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.74</td><td align="center" valign="middle" rowspan="1" colspan="1">Attachment of pedicle or flap graft to other sites</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">86.83</td><td align="center" valign="middle" rowspan="1" colspan="1">Size reduction plastic operation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dilation of rectum</td></tr></tbody></table></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-medsci-13-00055"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maaser</surname><given-names>C.</given-names></name>
<name><surname>Sturm</surname><given-names>A.</given-names></name>
<name><surname>Vavricka</surname><given-names>S.R.</given-names></name>
<name><surname>Kucharzik</surname><given-names>T.</given-names></name>
<name><surname>Fiorino</surname><given-names>G.</given-names></name>
<name><surname>Annese</surname><given-names>V.</given-names></name>
<name><surname>Calabrese</surname><given-names>E.</given-names></name>
<name><surname>Baumgart</surname><given-names>D.C.</given-names></name>
<name><surname>Bettenworth</surname><given-names>D.</given-names></name>
<name><surname>Borralho Nunes</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2019</year><volume>13</volume><fpage>144K</fpage><lpage>164K</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjy113</pub-id><pub-id pub-id-type="pmid">30137275</pub-id>
</element-citation></ref><ref id="B2-medsci-13-00055"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volkers</surname><given-names>A.G.</given-names></name>
<name><surname>Appleton</surname><given-names>L.</given-names></name>
<name><surname>Gearry</surname><given-names>R.B.</given-names></name>
<name><surname>Frampton</surname><given-names>C.M.</given-names></name>
<name><surname>De Voogd</surname><given-names>F.A.E.</given-names></name>
<name><surname>Peters Van Ton</surname><given-names>A.M.</given-names></name>
<name><surname>Leach</surname><given-names>S.T.</given-names></name>
<name><surname>Lemberg</surname><given-names>D.A.</given-names></name>
<name><surname>Day</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Fecal Calprotectin, Chitinase 3-Like-1, S100A12 and Osteoprotegerin as Markers of Disease Activity in Children with Crohn&#x02019;s Disease</article-title><source>Gastrointest. Disord.</source><year>2022</year><volume>4</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.3390/gidisord4030017</pub-id></element-citation></ref><ref id="B3-medsci-13-00055"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laterza</surname><given-names>L.</given-names></name>
<name><surname>Piscaglia</surname><given-names>A.C.</given-names></name>
<name><surname>Minordi</surname><given-names>L.M.</given-names></name>
<name><surname>Scoleri</surname><given-names>I.</given-names></name>
<name><surname>Larosa</surname><given-names>L.</given-names></name>
<name><surname>Poscia</surname><given-names>A.</given-names></name>
<name><surname>Ingravalle</surname><given-names>F.</given-names></name>
<name><surname>Amato</surname><given-names>A.</given-names></name>
<name><surname>Alfieri</surname><given-names>S.</given-names></name>
<name><surname>Armuzzi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn&#x02019;s Disease</article-title><source>Dig. Dis.</source><year>2018</year><volume>36</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1159/000487589</pub-id><pub-id pub-id-type="pmid">29514146</pub-id>
</element-citation></ref><ref id="B4-medsci-13-00055"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bohra</surname><given-names>A.</given-names></name>
<name><surname>Van Langenberg</surname><given-names>D.R.</given-names></name>
<name><surname>Vasudevan</surname><given-names>A.</given-names></name>
</person-group><article-title>Intestinal Ultrasound in the Assessment of Luminal Crohn&#x02019;s Disease</article-title><source>Gastrointest. Disord.</source><year>2022</year><volume>4</volume><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.3390/gidisord4040024</pub-id></element-citation></ref><ref id="B5-medsci-13-00055"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caviglia</surname><given-names>G.P.</given-names></name>
<name><surname>Garrone</surname><given-names>A.</given-names></name>
<name><surname>Bertolino</surname><given-names>C.</given-names></name>
<name><surname>Vanni</surname><given-names>R.</given-names></name>
<name><surname>Bretto</surname><given-names>E.</given-names></name>
<name><surname>Poshnjari</surname><given-names>A.</given-names></name>
<name><surname>Tribocco</surname><given-names>E.</given-names></name>
<name><surname>Frara</surname><given-names>S.</given-names></name>
<name><surname>Armandi</surname><given-names>A.</given-names></name>
<name><surname>Astegiano</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>641</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12020641</pub-id><pub-id pub-id-type="pmid">36675570</pub-id>
</element-citation></ref><ref id="B6-medsci-13-00055"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaplan</surname><given-names>G.G.</given-names></name>
</person-group><article-title>The global burden of IBD: From 2015 to 2025</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2015</year><volume>12</volume><fpage>720</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2015.150</pub-id><pub-id pub-id-type="pmid">26323879</pub-id>
</element-citation></ref><ref id="B7-medsci-13-00055"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>S.C.</given-names></name>
<name><surname>Shi</surname><given-names>H.Y.</given-names></name>
<name><surname>Hamidi</surname><given-names>N.</given-names></name>
<name><surname>Underwood</surname><given-names>F.E.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Benchimol</surname><given-names>E.I.</given-names></name>
<name><surname>Panaccione</surname><given-names>R.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>J.C.Y.</given-names></name>
<name><surname>Chan</surname><given-names>F.K.L.</given-names></name>
<etal/>
</person-group><article-title>Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>2769</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)32448-0</pub-id><pub-id pub-id-type="pmid">29050646</pub-id>
</element-citation></ref><ref id="B8-medsci-13-00055"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buie</surname><given-names>M.J.</given-names></name>
<name><surname>Quan</surname><given-names>J.</given-names></name>
<name><surname>Windsor</surname><given-names>J.W.</given-names></name>
<name><surname>Coward</surname><given-names>S.</given-names></name>
<name><surname>Hansen</surname><given-names>T.M.</given-names></name>
<name><surname>King</surname><given-names>J.A.</given-names></name>
<name><surname>Kotze</surname><given-names>P.G.</given-names></name>
<name><surname>Gearry</surname><given-names>R.B.</given-names></name>
<name><surname>Ng</surname><given-names>S.C.</given-names></name>
<name><surname>Mak</surname><given-names>J.W.Y.</given-names></name>
<etal/>
</person-group><article-title>Global Hospitalization Trends for Crohn&#x02019;s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review with Temporal Analyses</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2023</year><volume>21</volume><fpage>2211</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.06.030</pub-id><pub-id pub-id-type="pmid">35863682</pub-id>
</element-citation></ref><ref id="B9-medsci-13-00055"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dignass</surname><given-names>A.</given-names></name>
<name><surname>Rath</surname><given-names>S.</given-names></name>
<name><surname>Kleindienst</surname><given-names>T.</given-names></name>
<name><surname>Stallmach</surname><given-names>A.</given-names></name>
</person-group><article-title>Review article: Translating STRIDE-II into clinical reality&#x02014;Opportunities and challenges</article-title><source>Aliment. Pharmacol. Ther.</source><year>2023</year><volume>58</volume><fpage>492</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1111/apt.17622</pub-id><pub-id pub-id-type="pmid">37382397</pub-id>
</element-citation></ref><ref id="B10-medsci-13-00055"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marino</surname><given-names>M.G.</given-names></name>
<name><surname>Fusconi</surname><given-names>E.</given-names></name>
<name><surname>Magnatta</surname><given-names>R.</given-names></name>
<name><surname>Pan&#x000e0;</surname><given-names>A.</given-names></name>
<name><surname>Maurici</surname><given-names>M.</given-names></name>
</person-group><article-title>Epidemiologic Determinants Affecting Cigarette Smoking Cessation: A Retrospective Study in a National Health System (SSN) Treatment Service in Rome (Italy)</article-title><source>J. Environ. Public Health</source><year>2010</year><volume>2010</volume><fpage>183206</fpage><pub-id pub-id-type="doi">10.1155/2010/183206</pub-id><pub-id pub-id-type="pmid">20396671</pub-id>
</element-citation></ref><ref id="B11-medsci-13-00055"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaghini</surname><given-names>F.</given-names></name>
<name><surname>Vellone</surname><given-names>E.</given-names></name>
<name><surname>Maurici</surname><given-names>M.</given-names></name>
<name><surname>Sestili</surname><given-names>C.</given-names></name>
<name><surname>Mannocci</surname><given-names>A.</given-names></name>
<name><surname>Ercoli</surname><given-names>E.</given-names></name>
<name><surname>Magnavita</surname><given-names>N.</given-names></name>
<name><surname>La Torre</surname><given-names>G.</given-names></name>
<name><surname>Alvaro</surname><given-names>R.</given-names></name>
<name><surname>Sili</surname><given-names>A.</given-names></name>
</person-group><article-title>The influence of work context and organizational well-being on psychophysical health of healthcare providers</article-title><source>La Med. Del Lav.</source><year>2020</year><volume>111</volume><fpage>306</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.23749/mdl.v111i4.9075</pub-id></element-citation></ref><ref id="B12-medsci-13-00055"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seyedian</surname><given-names>S.S.</given-names></name>
<name><surname>Nokhostin</surname><given-names>F.</given-names></name>
<name><surname>Malamir</surname><given-names>M.D.</given-names></name>
</person-group><article-title>A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease</article-title><source>JMedLife</source><year>2019</year><volume>12</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.25122/jml-2018-0075</pub-id><pub-id pub-id-type="pmid">31406511</pub-id>
</element-citation></ref><ref id="B13-medsci-13-00055"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pietrantonio</surname><given-names>F.</given-names></name>
<name><surname>Vinci</surname><given-names>A.</given-names></name>
<name><surname>Maurici</surname><given-names>M.</given-names></name>
<name><surname>Ciarambino</surname><given-names>T.</given-names></name>
<name><surname>Galli</surname><given-names>B.</given-names></name>
<name><surname>Signorini</surname><given-names>A.</given-names></name>
<name><surname>La Fazia</surname><given-names>V.M.</given-names></name>
<name><surname>Rosselli</surname><given-names>F.</given-names></name>
<name><surname>Fortunato</surname><given-names>L.</given-names></name>
<name><surname>Iodice</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Intra- and Extra-Hospitalization Monitoring of Vital Signs&#x02014;Two Sides of the Same Coin: Perspectives from LIMS and Greenline-HT Study Operators</article-title><source>Sensors</source><year>2023</year><volume>23</volume><elocation-id>5408</elocation-id><pub-id pub-id-type="doi">10.3390/s23125408</pub-id><pub-id pub-id-type="pmid">37420575</pub-id>
</element-citation></ref><ref id="B14-medsci-13-00055"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pietrantonio</surname><given-names>F.</given-names></name>
<name><surname>Florczak</surname><given-names>M.</given-names></name>
<name><surname>Kuhn</surname><given-names>S.</given-names></name>
<name><surname>K&#x000e4;rberg</surname><given-names>K.</given-names></name>
<name><surname>Leung</surname><given-names>T.</given-names></name>
<name><surname>Said Criado</surname><given-names>I.</given-names></name>
<name><surname>Sikorski</surname><given-names>S.</given-names></name>
<name><surname>Ruggeri</surname><given-names>M.</given-names></name>
<name><surname>Signorini</surname><given-names>A.</given-names></name>
<name><surname>Rosiello</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Applications to augment patient care for Internal Medicine specialists: A position paper from the EFIM working group on telemedicine, innovative technologies &#x00026; digital health</article-title><source>Front. Public Health</source><year>2024</year><volume>12</volume><elocation-id>1370555</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2024.1370555</pub-id><pub-id pub-id-type="pmid">39005984</pub-id>
</element-citation></ref><ref id="B15-medsci-13-00055"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>H.</given-names></name>
<name><surname>Minozzi</surname><given-names>S.</given-names></name>
<name><surname>Kopylov</surname><given-names>U.</given-names></name>
<name><surname>Verstockt</surname><given-names>B.</given-names></name>
<name><surname>Chaparro</surname><given-names>M.</given-names></name>
<name><surname>Buskens</surname><given-names>C.</given-names></name>
<name><surname>Warusavitarne</surname><given-names>J.</given-names></name>
<name><surname>Agrawal</surname><given-names>M.</given-names></name>
<name><surname>Allocca</surname><given-names>M.</given-names></name>
<name><surname>Atreya</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>ECCO Guidelines on Therapeutics in Crohn&#x02019;s Disease: Medical Treatment</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2024</year><volume>18</volume><fpage>1531</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjae091</pub-id><pub-id pub-id-type="pmid">38877997</pub-id>
</element-citation></ref><ref id="B16-medsci-13-00055"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raine</surname><given-names>T.</given-names></name>
<name><surname>Bonovas</surname><given-names>S.</given-names></name>
<name><surname>Burisch</surname><given-names>J.</given-names></name>
<name><surname>Kucharzik</surname><given-names>T.</given-names></name>
<name><surname>Adamina</surname><given-names>M.</given-names></name>
<name><surname>Annese</surname><given-names>V.</given-names></name>
<name><surname>Bachmann</surname><given-names>O.</given-names></name>
<name><surname>Bettenworth</surname><given-names>D.</given-names></name>
<name><surname>Chaparro</surname><given-names>M.</given-names></name>
<name><surname>Czuber-Dochan</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2022</year><volume>16</volume><fpage>2</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjab178</pub-id><pub-id pub-id-type="pmid">34635919</pub-id>
</element-citation></ref><ref id="B17-medsci-13-00055"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vinci</surname><given-names>A.</given-names></name>
<name><surname>Ingravalle</surname><given-names>F.</given-names></name>
<name><surname>Bardhi</surname><given-names>D.</given-names></name>
<name><surname>Cesaro</surname><given-names>N.</given-names></name>
<name><surname>Frassino</surname><given-names>S.</given-names></name>
<name><surname>Licata</surname><given-names>F.</given-names></name>
<name><surname>Valvano</surname><given-names>M.</given-names></name>
</person-group><article-title>Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>2439</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10102439</pub-id><pub-id pub-id-type="pmid">36289701</pub-id>
</element-citation></ref><ref id="B18-medsci-13-00055"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arosa</surname><given-names>L.</given-names></name>
<name><surname>Camba-G&#x000f3;mez</surname><given-names>M.</given-names></name>
<name><surname>Conde-Aranda</surname><given-names>J.</given-names></name>
</person-group><article-title>Neutrophils in Intestinal Inflammation: What We Know and What We Could Expect for the Near Future</article-title><source>Gastrointest. Disord.</source><year>2022</year><volume>4</volume><fpage>263</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.3390/gidisord4040025</pub-id></element-citation></ref><ref id="B19-medsci-13-00055"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viscido</surname><given-names>A.</given-names></name>
<name><surname>Valvano</surname><given-names>M.</given-names></name>
<name><surname>Stefanelli</surname><given-names>G.</given-names></name>
<name><surname>Capannolo</surname><given-names>A.</given-names></name>
<name><surname>Castellini</surname><given-names>C.</given-names></name>
<name><surname>Onori</surname><given-names>E.</given-names></name>
<name><surname>Ciccone</surname><given-names>A.</given-names></name>
<name><surname>Vernia</surname><given-names>F.</given-names></name>
<name><surname>Latella</surname><given-names>G.</given-names></name>
</person-group><article-title>Systematic review and meta-analysis: The advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis</article-title><source>BMC Gastroenterol.</source><year>2022</year><volume>22</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-022-02157-5</pub-id><pub-id pub-id-type="pmid">35240984</pub-id>
</element-citation></ref><ref id="B20-medsci-13-00055"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maconi</surname><given-names>G.</given-names></name>
<name><surname>Lepore</surname><given-names>F.</given-names></name>
<name><surname>Saleh</surname><given-names>A.</given-names></name>
<name><surname>Saibeni</surname><given-names>S.</given-names></name>
<name><surname>Bezzio</surname><given-names>C.</given-names></name>
<name><surname>Cheli</surname><given-names>S.</given-names></name>
<name><surname>Massari</surname><given-names>A.</given-names></name>
<name><surname>Gridavilla</surname><given-names>D.</given-names></name>
<name><surname>Ferretti</surname><given-names>F.</given-names></name>
<name><surname>Cannatelli</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Factors correlated with transmural healing in patients with Crohn&#x02019;s disease in long-term clinical remission on anti-TNF medication</article-title><source>Dig. Liver Dis.</source><year>2024</year><volume>56</volume><fpage>2052</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2024.05.026</pub-id><pub-id pub-id-type="pmid">38897858</pub-id>
</element-citation></ref><ref id="B21-medsci-13-00055"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name>
<name><surname>Sandborn</surname><given-names>W.</given-names></name>
<name><surname>Sands</surname><given-names>B.E.</given-names></name>
<name><surname>Reinisch</surname><given-names>W.</given-names></name>
<name><surname>Bemelman</surname><given-names>W.</given-names></name>
<name><surname>Bryant</surname><given-names>R.V.</given-names></name>
<name><surname>D&#x02019;Haens</surname><given-names>G.</given-names></name>
<name><surname>Dotan</surname><given-names>I.</given-names></name>
<name><surname>Dubinsky</surname><given-names>M.</given-names></name>
<name><surname>Feagan</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target</article-title><source>Am. J. Gastroenterol.</source><year>2015</year><volume>110</volume><fpage>1324</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1038/ajg.2015.233</pub-id><pub-id pub-id-type="pmid">26303131</pub-id>
</element-citation></ref><ref id="B22-medsci-13-00055"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>D.</given-names></name>
<name><surname>Ricciuto</surname><given-names>A.</given-names></name>
<name><surname>Lewis</surname><given-names>A.</given-names></name>
<name><surname>D&#x02019;Amico</surname><given-names>F.</given-names></name>
<name><surname>Dhaliwal</surname><given-names>J.</given-names></name>
<name><surname>Griffiths</surname><given-names>A.M.</given-names></name>
<name><surname>Bettenworth</surname><given-names>D.</given-names></name>
<name><surname>Sandborn</surname><given-names>W.J.</given-names></name>
<name><surname>Sands</surname><given-names>B.E.</given-names></name>
<name><surname>Reinisch</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD</article-title><source>Gastroenterology</source><year>2021</year><volume>160</volume><fpage>1570</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.12.031</pub-id><pub-id pub-id-type="pmid">33359090</pub-id>
</element-citation></ref><ref id="B23-medsci-13-00055"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casella</surname><given-names>G.</given-names></name>
<name><surname>Ingravalle</surname><given-names>F.</given-names></name>
<name><surname>Ingravalle</surname><given-names>A.</given-names></name>
<name><surname>Monti</surname><given-names>C.</given-names></name>
<name><surname>Bonetti</surname><given-names>F.</given-names></name>
<name><surname>De Salvatore</surname><given-names>F.</given-names></name>
<name><surname>Villanacci</surname><given-names>V.</given-names></name>
<name><surname>Limonta</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccination in Inflammatory Bowel Disease: Utility and Future Perspective</article-title><source>Gastrointest. Disord.</source><year>2020</year><volume>2</volume><fpage>175</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.3390/gidisord2020019</pub-id></element-citation></ref><ref id="B24-medsci-13-00055"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bodini</surname><given-names>G.</given-names></name>
<name><surname>Giuliana</surname><given-names>E.</given-names></name>
<name><surname>Giberti</surname><given-names>I.</given-names></name>
<name><surname>Guarona</surname><given-names>G.</given-names></name>
<name><surname>Benvenuto</surname><given-names>F.</given-names></name>
<name><surname>Ferretti</surname><given-names>E.</given-names></name>
<name><surname>Demarzo</surname><given-names>M.G.</given-names></name>
<name><surname>Da Rin</surname><given-names>G.</given-names></name>
<name><surname>Icardi</surname><given-names>G.</given-names></name>
<name><surname>Giannini</surname><given-names>E.G.</given-names></name>
</person-group><article-title>Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment</article-title><source>Gastrointest. Disord.</source><year>2022</year><volume>4</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3390/gidisord4020009</pub-id></element-citation></ref><ref id="B25-medsci-13-00055"><label>25.</label><element-citation publication-type="gov"><article-title>Definizione e Aggiornamento dei Livelli Essenziali di Assistenza, di cui all&#x02019;articolo 1, Comma 7, del Decreto Legislativo 30 Dicembre. Decreto del Presidente del Consiglio dei Ministri. Sect. All. 8, G.U. Serie Generale n. 65</article-title><day>18</day><month>March</month><year>2017</year><comment>Available online: <ext-link xlink:href="https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=58669&#x00026;completo=true" ext-link-type="uri">https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=58669&#x00026;completo=true</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-29">(accessed on 29 April 2025)</date-in-citation></element-citation></ref><ref id="B26-medsci-13-00055"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheaff</surname><given-names>R.</given-names></name>
<name><surname>Morando</surname><given-names>V.</given-names></name>
<name><surname>Chambers</surname><given-names>N.</given-names></name>
<name><surname>Exworthy</surname><given-names>M.</given-names></name>
<name><surname>Mahon</surname><given-names>A.</given-names></name>
<name><surname>Byng</surname><given-names>R.</given-names></name>
<name><surname>Mannion</surname><given-names>R.</given-names></name>
</person-group><article-title>Managerial workarounds in three European DRG systems</article-title><source>J. Health Organ. Manag.</source><year>2020</year><volume>34</volume><fpage>295</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1108/JHOM-10-2019-0295</pub-id><pub-id pub-id-type="pmid">32364346</pub-id>
</element-citation></ref><ref id="B27-medsci-13-00055"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicholls</surname><given-names>S.G.</given-names></name>
<name><surname>Quach</surname><given-names>P.</given-names></name>
<name><surname>von Elm</surname><given-names>E.</given-names></name>
<name><surname>Guttmann</surname><given-names>A.</given-names></name>
<name><surname>Moher</surname><given-names>D.</given-names></name>
<name><surname>Petersen</surname><given-names>I.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>H.T.</given-names></name>
<name><surname>Smeeth</surname><given-names>L.</given-names></name>
<name><surname>Langan</surname><given-names>S.M.</given-names></name>
<name><surname>Benchimol</surname><given-names>E.I.</given-names></name>
</person-group><article-title>The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0125620</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0125620</pub-id><pub-id pub-id-type="pmid">25965407</pub-id>
</element-citation></ref><ref id="B28-medsci-13-00055"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furia</surname><given-names>G.</given-names></name>
<name><surname>Vinci</surname><given-names>A.</given-names></name>
<name><surname>Colamesta</surname><given-names>V.</given-names></name>
<name><surname>Papini</surname><given-names>P.</given-names></name>
<name><surname>Grossi</surname><given-names>A.</given-names></name>
<name><surname>Cammalleri</surname><given-names>V.</given-names></name>
<name><surname>Chierchini</surname><given-names>P.</given-names></name>
<name><surname>Maurici</surname><given-names>M.</given-names></name>
<name><surname>Damiani</surname><given-names>G.</given-names></name>
<name><surname>De Vito</surname><given-names>C.</given-names></name>
</person-group><article-title>Appropriateness of frequent use of emergency departments: A retrospective analysis in Rome, Italy</article-title><source>Front. Public Health</source><year>2023</year><volume>11</volume><elocation-id>1150511</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2023.1150511</pub-id><pub-id pub-id-type="pmid">37081951</pub-id>
</element-citation></ref><ref id="B29-medsci-13-00055"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murthy</surname><given-names>S.K.</given-names></name>
<name><surname>Begum</surname><given-names>J.</given-names></name>
<name><surname>Benchimol</surname><given-names>E.I.</given-names></name>
<name><surname>Bernstein</surname><given-names>C.N.</given-names></name>
<name><surname>Kaplan</surname><given-names>G.G.</given-names></name>
<name><surname>McCurdy</surname><given-names>J.D.</given-names></name>
<name><surname>Singh</surname><given-names>H.</given-names></name>
<name><surname>Targownik</surname><given-names>L.</given-names></name>
<name><surname>Taljaard</surname><given-names>M.</given-names></name>
</person-group><article-title>Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-318440</pub-id><pub-id pub-id-type="pmid">31196874</pub-id>
</element-citation></ref><ref id="B30-medsci-13-00055"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>J.K.</given-names></name>
<name><surname>Tan</surname><given-names>M.</given-names></name>
<name><surname>Stidham</surname><given-names>R.W.</given-names></name>
<name><surname>Colozzi</surname><given-names>J.</given-names></name>
<name><surname>Adams</surname><given-names>D.</given-names></name>
<name><surname>El-Serag</surname><given-names>H.</given-names></name>
<name><surname>Waljee</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Accuracy of Diagnostic Codes for Identifying Patients with Ulcerative Colitis and Crohn&#x02019;s Disease in the Veterans Affairs Health Care System</article-title><source>Dig. Dis. Sci.</source><year>2014</year><volume>59</volume><fpage>2406</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1007/s10620-014-3174-7</pub-id><pub-id pub-id-type="pmid">24817338</pub-id>
</element-citation></ref><ref id="B31-medsci-13-00055"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>M.</given-names></name>
<name><surname>King</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Measuring Business Cycles: Approximate Band-Pass Filters for Economic Time Series</article-title><source>Rev. Econ. Stat.</source><year>1999</year><volume>81</volume><fpage>575</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1162/003465399558454</pub-id></element-citation></ref><ref id="B32-medsci-13-00055"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuenzig</surname><given-names>M.E.</given-names></name>
<name><surname>Fung</surname><given-names>S.G.</given-names></name>
<name><surname>Marderfeld</surname><given-names>L.</given-names></name>
<name><surname>Mak</surname><given-names>J.W.Y.</given-names></name>
<name><surname>Kaplan</surname><given-names>G.G.</given-names></name>
<name><surname>Ng</surname><given-names>S.C.</given-names></name>
<name><surname>Wilson</surname><given-names>D.C.</given-names></name>
<name><surname>Cameron</surname><given-names>F.</given-names></name>
<name><surname>Henderson</surname><given-names>P.</given-names></name>
<name><surname>Kotze</surname><given-names>P.G.</given-names></name>
<etal/>
</person-group><article-title>Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review</article-title><source>Gastroenterology</source><year>2022</year><volume>162</volume><fpage>1147</fpage><lpage>1159.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2021.12.282</pub-id><pub-id pub-id-type="pmid">34995526</pub-id>
</element-citation></ref><ref id="B33-medsci-13-00055"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
</person-group><article-title>Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e065186</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-065186</pub-id></element-citation></ref><ref id="B34-medsci-13-00055"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szilagyi</surname><given-names>A.</given-names></name>
</person-group><article-title>Relationship(s) between obesity and inflammatory bowel diseases: Possible intertwined pathogenic mechanisms</article-title><source>Clin. J. Gastroenterol.</source><year>2020</year><volume>13</volume><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s12328-019-01037-y</pub-id><pub-id pub-id-type="pmid">31452062</pub-id>
</element-citation></ref><ref id="B35-medsci-13-00055"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name>
<name><surname>Loftus</surname><given-names>E.V.</given-names></name>
<name><surname>Colombel</surname><given-names>J.-F.</given-names></name>
<name><surname>Sandborn</surname><given-names>W.J.</given-names></name>
</person-group><article-title>The Natural History of Adult Crohn&#x02019;s Disease in Population-Based Cohorts</article-title><source>Am. J. Gastroenterol.</source><year>2010</year><volume>105</volume><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.579</pub-id><pub-id pub-id-type="pmid">19861953</pub-id>
</element-citation></ref><ref id="B36-medsci-13-00055"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solberg</surname><given-names>I.C.</given-names></name>
<name><surname>Vatn</surname><given-names>M.H.</given-names></name>
<name><surname>H&#x000f8;ie</surname><given-names>O.</given-names></name>
<name><surname>Stray</surname><given-names>N.</given-names></name>
<name><surname>Sauar</surname><given-names>J.</given-names></name>
<name><surname>Jahnsen</surname><given-names>J.</given-names></name>
<name><surname>Moum</surname><given-names>B.</given-names></name>
<name><surname>Lygren</surname><given-names>I.</given-names></name>
</person-group><article-title>Clinical Course in Crohn&#x02019;s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2007</year><volume>5</volume><fpage>1430</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2007.09.002</pub-id><pub-id pub-id-type="pmid">18054751</pub-id>
</element-citation></ref><ref id="B37-medsci-13-00055"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenkinson</surname><given-names>P.W.</given-names></name>
<name><surname>Plevris</surname><given-names>N.</given-names></name>
<name><surname>Siakavellas</surname><given-names>S.</given-names></name>
<name><surname>Lyons</surname><given-names>M.</given-names></name>
<name><surname>Arnott</surname><given-names>I.D.</given-names></name>
<name><surname>Wilson</surname><given-names>D.</given-names></name>
<name><surname>Watson</surname><given-names>A.J.M.</given-names></name>
<name><surname>Jones</surname><given-names>G.-R.</given-names></name>
<name><surname>Lees</surname><given-names>C.W.</given-names></name>
</person-group><article-title>Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn&#x02019;s Disease: A Population-based Cohort Study</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2020</year><volume>14</volume><fpage>1241</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa044</pub-id><pub-id pub-id-type="pmid">32840295</pub-id>
</element-citation></ref><ref id="B38-medsci-13-00055"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valvano</surname><given-names>M.</given-names></name>
<name><surname>Vinci</surname><given-names>A.</given-names></name>
<name><surname>Cesaro</surname><given-names>N.</given-names></name>
<name><surname>Frassino</surname><given-names>S.</given-names></name>
<name><surname>Ingravalle</surname><given-names>F.</given-names></name>
<name><surname>Ameli</surname><given-names>M.</given-names></name>
<name><surname>Viscido</surname><given-names>A.</given-names></name>
<name><surname>Necozione</surname><given-names>S.</given-names></name>
<name><surname>Latella</surname><given-names>G.</given-names></name>
</person-group><article-title>The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn&#x02019;s disease in real world-data: A retrospective study</article-title><source>BMC Gastroenterol.</source><year>2023</year><volume>23</volume><elocation-id>438</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-023-03074-x</pub-id><pub-id pub-id-type="pmid">38097975</pub-id>
</element-citation></ref><ref id="B39-medsci-13-00055"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aratari</surname><given-names>A.</given-names></name>
<name><surname>Scribano</surname><given-names>M.L.</given-names></name>
<name><surname>Pugliese</surname><given-names>D.</given-names></name>
<name><surname>Baccolini</surname><given-names>V.</given-names></name>
<name><surname>De Biasio</surname><given-names>F.</given-names></name>
<name><surname>Verna</surname><given-names>S.</given-names></name>
<name><surname>Morretta</surname><given-names>C.</given-names></name>
<name><surname>Festa</surname><given-names>S.</given-names></name>
<name><surname>Armuzzi</surname><given-names>A.</given-names></name>
<name><surname>Papi</surname><given-names>C.</given-names></name>
</person-group><article-title>Crohn&#x02019;s disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate&#x02014;A retrospective multicentre real-world study</article-title><source>Aliment. Pharmacol. Ther.</source><year>2024</year><volume>59</volume><fpage>1579</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1111/apt.18001</pub-id><pub-id pub-id-type="pmid">38616417</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="medsci-13-00055-f001"><label>Figure 1</label><caption><p>Gantt chart of data availability and cohort composition timelines. Shaded areas indicate incomplete or partial data coverage for the year.</p></caption><graphic xlink:href="medsci-13-00055-g001" position="float"/></fig><fig position="float" id="medsci-13-00055-f002"><label>Figure 2</label><caption><p>IBD monthly incidence (&#x000d7;100,000 ppl) with trend component (with 95% Confidence Interval) and linear fit; 2011&#x02013;2021.</p></caption><graphic xlink:href="medsci-13-00055-g002" position="float"/></fig><fig position="float" id="medsci-13-00055-f003"><label>Figure 3</label><caption><p>IBD prevalence at May 2024: age and gender composition.</p></caption><graphic xlink:href="medsci-13-00055-g003" position="float"/></fig><fig position="float" id="medsci-13-00055-f004"><label>Figure 4</label><caption><p>Unadjusted IBD-related hospitalisations, 2018&#x02013;2024.</p></caption><graphic xlink:href="medsci-13-00055-g004" position="float"/></fig><fig position="float" id="medsci-13-00055-f005"><label>Figure 5</label><caption><p>Kaplan&#x02013;Meier failure functions for Ulcerative Colitis (UC) and Crohn&#x02019;s Disease (CD) patients, raw data (<bold>left</bold>), and adjusted for age at diagnosis and gender (<bold>right</bold>). The outcome of interest is the first occurrence of surgery.</p></caption><graphic xlink:href="medsci-13-00055-g005" position="float"/></fig><table-wrap position="float" id="medsci-13-00055-t001"><object-id pub-id-type="pii">medsci-13-00055-t001_Table 1</object-id><label>Table 1</label><caption><p>Raw incidence of IBD by age range and standardised incidence &#x000d7; 100,000 ab (ref. population: 2024 LHA Roma 1 residents); 2011&#x02013;2021. UC: Ulcerative colitis. CD: Crohn&#x02019;s Disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IBD Cases</th><th colspan="10" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age at Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Age-Standardised Incidence &#x000d7; 100,000 PPL</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;10</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;20</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;30</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;40</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#x02013;50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#x02013;60</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#x02013;70</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70&#x02013;80</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;90</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90&#x02013;100</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2011</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">8.83</td><td align="center" valign="middle" rowspan="1" colspan="1">5.83</td><td align="center" valign="middle" rowspan="1" colspan="1">14.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2012</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">175</td><td align="center" valign="middle" rowspan="1" colspan="1">9.22</td><td align="center" valign="middle" rowspan="1" colspan="1">4.81</td><td align="center" valign="middle" rowspan="1" colspan="1">14.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2013</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">313</td><td align="center" valign="middle" rowspan="1" colspan="1">16.13</td><td align="center" valign="middle" rowspan="1" colspan="1">9.45</td><td align="center" valign="middle" rowspan="1" colspan="1">25.58</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2014</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">214</td><td align="center" valign="middle" rowspan="1" colspan="1">11.30</td><td align="center" valign="middle" rowspan="1" colspan="1">5.81</td><td align="center" valign="middle" rowspan="1" colspan="1">17.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2015</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">300</td><td align="center" valign="middle" rowspan="1" colspan="1">16.05</td><td align="center" valign="middle" rowspan="1" colspan="1">8.18</td><td align="center" valign="middle" rowspan="1" colspan="1">24.23</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2016</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">54</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">280</td><td align="center" valign="middle" rowspan="1" colspan="1">14.63</td><td align="center" valign="middle" rowspan="1" colspan="1">8.19</td><td align="center" valign="middle" rowspan="1" colspan="1">22.82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2017</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">192</td><td align="center" valign="middle" rowspan="1" colspan="1">9.60</td><td align="center" valign="middle" rowspan="1" colspan="1">6.07</td><td align="center" valign="middle" rowspan="1" colspan="1">15.68</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2018</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">299</td><td align="center" valign="middle" rowspan="1" colspan="1">15.59</td><td align="center" valign="middle" rowspan="1" colspan="1">9.21</td><td align="center" valign="middle" rowspan="1" colspan="1">24.79</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2019</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">315</td><td align="center" valign="middle" rowspan="1" colspan="1">16.95</td><td align="center" valign="middle" rowspan="1" colspan="1">8.36</td><td align="center" valign="middle" rowspan="1" colspan="1">25.31</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2020</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">246</td><td align="center" valign="middle" rowspan="1" colspan="1">13.99</td><td align="center" valign="middle" rowspan="1" colspan="1">6.16</td><td align="center" valign="middle" rowspan="1" colspan="1">20.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2021</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">341</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.54</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>20</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>149</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>293</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>492</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>619</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>632</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>404</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>205</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>44</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2859</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>-</bold>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="medsci-13-00055-t002"><object-id pub-id-type="pii">medsci-13-00055-t002_Table 2</object-id><label>Table 2</label><caption><p>Demographic composition of prospective cohort. UC: Ulcerative colitis; CD: Crohn&#x02019;s Disease; IQR: Interquartile range; SD: Standard Deviation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD: N = 194</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">UC: N = 362</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at diagnosis (mean; SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">47.0; 15.9</td><td align="center" valign="middle" rowspan="1" colspan="1">48.5; 15.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male (N; %)</td><td align="center" valign="middle" rowspan="1" colspan="1">109; 56.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">190; 52.5%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total interventions (N; %)</td><td align="center" valign="middle" rowspan="1" colspan="1">21; 10.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">36; 9.9%</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median follow-up duration (months; IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.7 (50.9&#x02013;69.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.1 (49.2&#x02013;65.5)</td></tr></tbody></table></table-wrap></floats-group></article>